Prema Cognition, a digital health company developing technology for the early detection of dementia, has raised £550,000 in funding led by SFC Capital. Prema Cognition initially set out to raise £500,000, ultimately exceeding its target due to strong investor demand.
The funding will support the expansion of clinical datasets to further validate the technology, alongside progress towards regulatory pathways and broader deployment across healthcare and research settings. PREMAZ, Prema Cognition’s memory test, is designed to detect subtle changes in memory that can appear decades before a formal dementia diagnosis and identify at-risk patients years earlier than existing tools.
Co-founded by Dr Julia Cooney, MD, who was named to the Forbes 30 Under 30 list this year, and commercial lead Cameron Kirkpatrick, Prema Cognition is developing a digital cognitive testing platform for early brain health detection. PREMAZ was developed from a decade of research at the University of Cambridge Memory Lab and is already deployed in 30+ clinics across the UK and US, with ongoing expansion across healthcare and research settings.
Alongside SFC Capital, the round brings together angel investors spanning pharma, biotech, enterprise software, and longevity, including follow-on investment from existing backers and new strategic angels. Investors include Jasbir Singh, Steve Hartman, Keith Williams and Yin Chao Lee.
Prema Cognition is further supported by a scientific and clinical advisory group, including Dr Helena Gellersen, a postdoctoral researcher at the University of Cambridge whose work on memory precision underpins the technology, and Dr Ravi Badge, a consultant orthopaedic surgeon and sports medicine specialist who advises on clinical pathways and applications in contact sport populations. Prema Cognition will present at the Alzheimer’s Association International Conference in London this July, as it continues to generate and validate real-world data to support broader adoption across clinical and research environments.
Many new therapies for Alzheimer’s disease and related conditions are designed to work at the earliest stages of the disease process. However, most existing cognitive tests detect impairment only once irreversible damage has already occurred. Our test shifts the detection window years earlier, providing a far more sensitive way of identifying subtle changes in memory.
